The “transition period” that Bristol Myers Squibb CEO Chris Boerner promised was coming to the company appears to have arrived.
On Thursday, the pharma giant said it would undertake $1.5 billion in cost-cutting measures, including changes to the pipeline and the company’s workforce. Bristol Myers will reduce its workforce by 2,200 people by the end of the year, a company spokesperson said. BMS’ stock $BMY was down more than 8% in early Thursday trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.